Rhodojaponin VI is an orally active diterpenoid compound found in hododendron molle G. Don ( Ericaceae ) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the MDM2-Notch1 signalling pathway by reducing MDM2 and Notch1 expression. Rhodojaponin VI indirectly reduces Cav 2.2 current intensity by inhibiting NSF -mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Renal Disease | Products > Disease Areas > Genitourinary Inflammation | Products > Disease Areas > Pain | Products > Disease Areas > Nephritis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > Notch | Products > Signaling Pathways > Calcium Channel
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.